Illumina Inc

ILU.DE | Healthcare | XETRA
$118.52
+0.02 (+0.02%)

Key Metrics

Market Cap
$17.93B
P/E Ratio
25.27
EPS
$4.69
Beta
N/A
Dividend Yield
N/A
ROE
34.01%
Current Ratio
1.75

Company Information

Industry
Medical Diagnostics Research

About Illumina Inc

Illumina Inc provides sequencing and arraybased solutions for genetic and genomic analysis Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences oncology reproductive health agriculture and other emerging segments The company provides instruments and consumables used in genetic analysis and genotyping and sequencing services instrument service contracts and development and licensing agreements as well as cancer detection testing services Its customers include genomic research centers academic institutions government laboratories and hospitals as well as pharmaceutical biotechnology commercial molecular diagnostic laboratories and consumer genomics companies The company markets and distributes its products directly to customers in North America Europe Latin America and the AsiaPacific region as well as sells through lifescience distributors in various markets within Europe the AsiaPacific region Latin America the Middle East and Africa The company was incorporated in 1998 and is based in San Diego California

Recent Earnings Surprises

Date Actual EPS Estimated EPS Surprise
2026-04-30 $1.00 $0.91 +9.0%
2026-02-05 $1.15 $1.06 +8.5%
2025-10-30 $0.82 $1.00 -18.2%
2025-07-31 $1.27 $0.86 +47.8%

Financial Ratios (TTM)

Gross Margin
66.71%
Operating Margin
21.24%
Net Margin
19.43%
ROA
13.05%
Price to Book
8.02
Price to Sales
4.82